BBIO: BridgeBio Pharma Inc

BBIO新闻

• 15:58 Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87
• 12:06 The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
• 13:30 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
• 20:49 Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91
• 16:21 Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120
• 13:00 BridgeBio Stock: Additional Encaleret Data ADH1 And Three Expected FDA Reviews
• 07:04 Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care
• 07:04 报告称，BridgeBio 的 Encaleret 提高了骨转换，3 期 CALIBRATE 研究中 100% 的参与者至少一项 ADH1 症状得到改善，而标准治疗组为 46%
• 06:56 Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations
• 06:56 据报道，BridgeBio在HFSA 2026上展示Acoramidis数据：在一项针对2,684名ATTR-CM患者的真实世界研究中，与Tafamidis相比，复合风险降低18%，且心血管住院后死亡率上升
• 14:37 FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
• 13:33 巴克莱维持对 BridgeBio Pharma 的增持评级，将目标价下调至 156 美元
• 13:33 Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156
• 20:03 BridgeBio宣布将在10月9日至12日举行的HFSA大会上展示Attruby淀粉样心脏病数据，包括与替米地司的真实世界比较
• 20:02 BridgeBio宣布将于10月11日在ASBMR上展示遗传性低钙血症ADH1中Encaleret的额外III期数据
• 11:32 BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia